ASH 2018 | Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma

Vincent Rajkumar

Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, discusses the results of the TOURMALINE-MM3 trial (NCT02181413) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Maintenance therapy with ixazomib, an oral proteasome inhibitor, was found to significantly prolong progression-free survival following autologous stem cell transplantation in newly diagnosed multiple myeloma.

Share this video